nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—PTK6—Vandetanib—thyroid cancer	0.059	0.0824	CbGbCtD
Dasatinib—RIPK2—Vandetanib—thyroid cancer	0.0427	0.0596	CbGbCtD
Dasatinib—ZAK—Sorafenib—thyroid cancer	0.0356	0.0496	CbGbCtD
Dasatinib—EPHA5—Vandetanib—thyroid cancer	0.0339	0.0473	CbGbCtD
Dasatinib—STK35—Vandetanib—thyroid cancer	0.0339	0.0473	CbGbCtD
Dasatinib—BMPR1B—Vandetanib—thyroid cancer	0.0339	0.0473	CbGbCtD
Dasatinib—FYN—Vandetanib—thyroid cancer	0.0339	0.0473	CbGbCtD
Dasatinib—ERBB3—Vandetanib—thyroid cancer	0.0339	0.0473	CbGbCtD
Dasatinib—EPHA8—Vandetanib—thyroid cancer	0.0284	0.0396	CbGbCtD
Dasatinib—MAP4K5—Vandetanib—thyroid cancer	0.0284	0.0396	CbGbCtD
Dasatinib—YES1—Vandetanib—thyroid cancer	0.0284	0.0396	CbGbCtD
Dasatinib—FGR—Vandetanib—thyroid cancer	0.0245	0.0342	CbGbCtD
Dasatinib—BLK—Vandetanib—thyroid cancer	0.0217	0.0302	CbGbCtD
Dasatinib—LYN—Vandetanib—thyroid cancer	0.0217	0.0302	CbGbCtD
Dasatinib—EPHB6—Vandetanib—thyroid cancer	0.0217	0.0302	CbGbCtD
Dasatinib—SRC—Vandetanib—thyroid cancer	0.0217	0.0302	CbGbCtD
Dasatinib—ABL2—Vandetanib—thyroid cancer	0.0195	0.0272	CbGbCtD
Dasatinib—LCK—Vandetanib—thyroid cancer	0.0177	0.0247	CbGbCtD
Dasatinib—MAP2K5—Vandetanib—thyroid cancer	0.0177	0.0247	CbGbCtD
Dasatinib—PDGFRB—Vandetanib—thyroid cancer	0.0177	0.0247	CbGbCtD
Dasatinib—FMO3—Vandetanib—thyroid cancer	0.0177	0.0247	CbGbCtD
Dasatinib—MAP3K19—Vandetanib—thyroid cancer	0.0163	0.0227	CbGbCtD
Dasatinib—ABL1—Vandetanib—thyroid cancer	0.0141	0.0196	CbGbCtD
Dasatinib—EPHB6—Sorafenib—thyroid cancer	0.0131	0.0182	CbGbCtD
Dasatinib—KIT—Sorafenib—thyroid cancer	0.0117	0.0164	CbGbCtD
Dasatinib—PDGFRA—Sorafenib—thyroid cancer	0.0117	0.0164	CbGbCtD
Dasatinib—CSF1R—Sorafenib—thyroid cancer	0.0117	0.0164	CbGbCtD
Dasatinib—PDGFRB—Sorafenib—thyroid cancer	0.0107	0.0149	CbGbCtD
Dasatinib—MAP2K5—Sorafenib—thyroid cancer	0.0107	0.0149	CbGbCtD
Dasatinib—MAP3K19—Sorafenib—thyroid cancer	0.00982	0.0137	CbGbCtD
Dasatinib—ABCG2—Vandetanib—thyroid cancer	0.00321	0.00449	CbGbCtD
Dasatinib—CYP1B1—Doxorubicin—thyroid cancer	0.00247	0.00345	CbGbCtD
Dasatinib—ABCG2—Sorafenib—thyroid cancer	0.00194	0.0027	CbGbCtD
Dasatinib—PKMYT1—neck—thyroid cancer	0.00135	0.0206	CbGeAlD
Dasatinib—ABCG2—Doxorubicin—thyroid cancer	0.00118	0.00164	CbGbCtD
Dasatinib—CYP3A5—Sorafenib—thyroid cancer	0.00107	0.0015	CbGbCtD
Dasatinib—PKMYT1—Afatinib—Vandetanib—thyroid cancer	0.00103	0.423	CbGdCrCtD
Dasatinib—MYT1—head—thyroid cancer	0.000991	0.0151	CbGeAlD
Dasatinib—PTK6—saliva-secreting gland—thyroid cancer	0.000962	0.0147	CbGeAlD
Dasatinib—TEC—thyroid gland—thyroid cancer	0.00095	0.0145	CbGeAlD
Dasatinib—CYP1A2—Sorafenib—thyroid cancer	0.000799	0.00112	CbGbCtD
Dasatinib—EPHB1—thyroid gland—thyroid cancer	0.000746	0.0114	CbGeAlD
Dasatinib—PTK6—trachea—thyroid cancer	0.000742	0.0113	CbGeAlD
Dasatinib—ABCB1—Sorafenib—thyroid cancer	0.000699	0.000975	CbGbCtD
Dasatinib—CYP3A4—Vandetanib—thyroid cancer	0.000694	0.000969	CbGbCtD
Dasatinib—TESK1—saliva-secreting gland—thyroid cancer	0.000672	0.0103	CbGeAlD
Dasatinib—EPHB3—saliva-secreting gland—thyroid cancer	0.000662	0.0101	CbGeAlD
Dasatinib—EPHB1—head—thyroid cancer	0.000661	0.0101	CbGeAlD
Dasatinib—MAPK14—neck—thyroid cancer	0.000653	0.00997	CbGeAlD
Dasatinib—PKMYT1—thyroid gland—thyroid cancer	0.000642	0.00979	CbGeAlD
Dasatinib—BMX—thyroid gland—thyroid cancer	0.000626	0.00956	CbGeAlD
Dasatinib—CSK—saliva-secreting gland—thyroid cancer	0.000616	0.0094	CbGeAlD
Dasatinib—TEC—lymph node—thyroid cancer	0.00059	0.00901	CbGeAlD
Dasatinib—SIK2—head—thyroid cancer	0.000584	0.00892	CbGeAlD
Dasatinib—RIPK2—saliva-secreting gland—thyroid cancer	0.000572	0.00872	CbGeAlD
Dasatinib—PKMYT1—head—thyroid cancer	0.000569	0.00869	CbGeAlD
Dasatinib—SIK1—saliva-secreting gland—thyroid cancer	0.000558	0.00852	CbGeAlD
Dasatinib—STAT5B—thyroid gland—thyroid cancer	0.000555	0.00847	CbGeAlD
Dasatinib—ERBB3—saliva-secreting gland—thyroid cancer	0.000547	0.00835	CbGeAlD
Dasatinib—EPHB2—head—thyroid cancer	0.000543	0.00829	CbGeAlD
Dasatinib—SRMS—head—thyroid cancer	0.000532	0.00811	CbGeAlD
Dasatinib—TXK—head—thyroid cancer	0.000526	0.00803	CbGeAlD
Dasatinib—EPHA8—head—thyroid cancer	0.000521	0.00795	CbGeAlD
Dasatinib—TESK1—trachea—thyroid cancer	0.000519	0.00791	CbGeAlD
Dasatinib—EPHA3—thyroid gland—thyroid cancer	0.000513	0.00783	CbGeAlD
Dasatinib—STK36—trachea—thyroid cancer	0.00051	0.00779	CbGeAlD
Dasatinib—EPHB3—trachea—thyroid cancer	0.00051	0.00779	CbGeAlD
Dasatinib—SIK3—thyroid gland—thyroid cancer	0.000499	0.00762	CbGeAlD
Dasatinib—LIMK2—trachea—thyroid cancer	0.000493	0.00753	CbGeAlD
Dasatinib—STAT5B—head—thyroid cancer	0.000492	0.00751	CbGeAlD
Dasatinib—EPHB4—saliva-secreting gland—thyroid cancer	0.000483	0.00737	CbGeAlD
Dasatinib—CSK—trachea—thyroid cancer	0.000475	0.00725	CbGeAlD
Dasatinib—EPHA2—saliva-secreting gland—thyroid cancer	0.000474	0.00723	CbGeAlD
Dasatinib—HCK—trachea—thyroid cancer	0.000469	0.00716	CbGeAlD
Dasatinib—ZAK—thyroid gland—thyroid cancer	0.000464	0.00708	CbGeAlD
Dasatinib—EPHB1—lymph node—thyroid cancer	0.000463	0.00707	CbGeAlD
Dasatinib—MAP4K5—saliva-secreting gland—thyroid cancer	0.000462	0.00705	CbGeAlD
Dasatinib—MAP3K3—saliva-secreting gland—thyroid cancer	0.000462	0.00705	CbGeAlD
Dasatinib—EPHA3—head—thyroid cancer	0.000455	0.00695	CbGeAlD
Dasatinib—BMPR1B—thyroid gland—thyroid cancer	0.000445	0.00679	CbGeAlD
Dasatinib—SIK3—head—thyroid cancer	0.000443	0.00676	CbGeAlD
Dasatinib—BTK—thyroid gland—thyroid cancer	0.000443	0.00676	CbGeAlD
Dasatinib—EPHB6—saliva-secreting gland—thyroid cancer	0.000442	0.00674	CbGeAlD
Dasatinib—RIPK2—trachea—thyroid cancer	0.000441	0.00673	CbGeAlD
Dasatinib—TNK2—thyroid gland—thyroid cancer	0.000436	0.00666	CbGeAlD
Dasatinib—KIT—neck—thyroid cancer	0.000429	0.00655	CbGeAlD
Dasatinib—YES1—saliva-secreting gland—thyroid cancer	0.000427	0.00651	CbGeAlD
Dasatinib—EPHA4—trachea—thyroid cancer	0.000426	0.0065	CbGeAlD
Dasatinib—ABCB1—Doxorubicin—thyroid cancer	0.000424	0.000592	CbGbCtD
Dasatinib—ERBB3—trachea—thyroid cancer	0.000422	0.00644	CbGeAlD
Dasatinib—PDGFRB—neck—thyroid cancer	0.000419	0.0064	CbGeAlD
Dasatinib—CYP3A4—Sorafenib—thyroid cancer	0.000419	0.000584	CbGbCtD
Dasatinib—ZAK—head—thyroid cancer	0.000412	0.00628	CbGeAlD
Dasatinib—TESK1—thyroid gland—thyroid cancer	0.00041	0.00626	CbGeAlD
Dasatinib—STK36—thyroid gland—thyroid cancer	0.000404	0.00616	CbGeAlD
Dasatinib—EPHA5—head—thyroid cancer	0.000403	0.00615	CbGeAlD
Dasatinib—LYN—head—thyroid cancer	0.000401	0.00612	CbGeAlD
Dasatinib—BMPR1B—head—thyroid cancer	0.000395	0.00602	CbGeAlD
Dasatinib—MAP3K19—head—thyroid cancer	0.000395	0.00602	CbGeAlD
Dasatinib—LCK—trachea—thyroid cancer	0.000391	0.00597	CbGeAlD
Dasatinib—LIMK2—thyroid gland—thyroid cancer	0.00039	0.00596	CbGeAlD
Dasatinib—BMX—lymph node—thyroid cancer	0.000389	0.00594	CbGeAlD
Dasatinib—TNK2—head—thyroid cancer	0.000387	0.00591	CbGeAlD
Dasatinib—BLK—lymph node—thyroid cancer	0.000385	0.00587	CbGeAlD
Dasatinib—STK35—thyroid gland—thyroid cancer	0.000378	0.00577	CbGeAlD
Dasatinib—MAP2K5—saliva-secreting gland—thyroid cancer	0.000378	0.00576	CbGeAlD
Dasatinib—CSK—thyroid gland—thyroid cancer	0.000376	0.00573	CbGeAlD
Dasatinib—EPHB4—trachea—thyroid cancer	0.000373	0.00568	CbGeAlD
Dasatinib—HCK—thyroid gland—thyroid cancer	0.000371	0.00566	CbGeAlD
Dasatinib—JAK2—trachea—thyroid cancer	0.00037	0.00564	CbGeAlD
Dasatinib—ABL2—thyroid gland—thyroid cancer	0.000369	0.00563	CbGeAlD
Dasatinib—TXK—lymph node—thyroid cancer	0.000368	0.00562	CbGeAlD
Dasatinib—EPHA2—trachea—thyroid cancer	0.000365	0.00558	CbGeAlD
Dasatinib—FYN—trachea—thyroid cancer	0.000365	0.00557	CbGeAlD
Dasatinib—TESK1—head—thyroid cancer	0.000364	0.00555	CbGeAlD
Dasatinib—EPHB3—head—thyroid cancer	0.000358	0.00546	CbGeAlD
Dasatinib—STK36—head—thyroid cancer	0.000358	0.00546	CbGeAlD
Dasatinib—MAP3K3—trachea—thyroid cancer	0.000357	0.00544	CbGeAlD
Dasatinib—MAP4K5—trachea—thyroid cancer	0.000357	0.00544	CbGeAlD
Dasatinib—RIPK2—thyroid gland—thyroid cancer	0.000349	0.00532	CbGeAlD
Dasatinib—LIMK2—head—thyroid cancer	0.000346	0.00528	CbGeAlD
Dasatinib—STAT5B—lymph node—thyroid cancer	0.000345	0.00526	CbGeAlD
Dasatinib—EPHB6—trachea—thyroid cancer	0.000341	0.0052	CbGeAlD
Dasatinib—SIK1—thyroid gland—thyroid cancer	0.000341	0.0052	CbGeAlD
Dasatinib—EPHA4—thyroid gland—thyroid cancer	0.000337	0.00514	CbGeAlD
Dasatinib—STK35—head—thyroid cancer	0.000336	0.00512	CbGeAlD
Dasatinib—KIT—saliva-secreting gland—thyroid cancer	0.000335	0.00511	CbGeAlD
Dasatinib—ERBB3—thyroid gland—thyroid cancer	0.000334	0.00509	CbGeAlD
Dasatinib—CSK—head—thyroid cancer	0.000333	0.00509	CbGeAlD
Dasatinib—MAP3K2—thyroid gland—thyroid cancer	0.000331	0.00505	CbGeAlD
Dasatinib—YES1—trachea—thyroid cancer	0.000329	0.00502	CbGeAlD
Dasatinib—HCK—head—thyroid cancer	0.000329	0.00502	CbGeAlD
Dasatinib—PDGFRB—saliva-secreting gland—thyroid cancer	0.000327	0.00499	CbGeAlD
Dasatinib—PDGFRA—trachea—thyroid cancer	0.000323	0.00493	CbGeAlD
Dasatinib—EPHA3—lymph node—thyroid cancer	0.000319	0.00486	CbGeAlD
Dasatinib—MAPK14—thyroid gland—thyroid cancer	0.000311	0.00474	CbGeAlD
Dasatinib—SIK3—lymph node—thyroid cancer	0.00031	0.00473	CbGeAlD
Dasatinib—FGR—thyroid gland—thyroid cancer	0.00031	0.00472	CbGeAlD
Dasatinib—LCK—thyroid gland—thyroid cancer	0.00031	0.00472	CbGeAlD
Dasatinib—RIPK2—head—thyroid cancer	0.000309	0.00472	CbGeAlD
Dasatinib—SIK1—head—thyroid cancer	0.000302	0.00461	CbGeAlD
Dasatinib—EPHA4—head—thyroid cancer	0.000299	0.00456	CbGeAlD
Dasatinib—FMO3—thyroid gland—thyroid cancer	0.000299	0.00456	CbGeAlD
Dasatinib—ERBB3—head—thyroid cancer	0.000296	0.00452	CbGeAlD
Dasatinib—EPHB4—thyroid gland—thyroid cancer	0.000295	0.0045	CbGeAlD
Dasatinib—MAP3K2—head—thyroid cancer	0.000293	0.00448	CbGeAlD
Dasatinib—JAK2—thyroid gland—thyroid cancer	0.000293	0.00447	CbGeAlD
Dasatinib—ABL1—saliva-secreting gland—thyroid cancer	0.000291	0.00445	CbGeAlD
Dasatinib—MAP2K5—trachea—thyroid cancer	0.000291	0.00445	CbGeAlD
Dasatinib—EPHA2—thyroid gland—thyroid cancer	0.000289	0.00441	CbGeAlD
Dasatinib—FYN—thyroid gland—thyroid cancer	0.000289	0.0044	CbGeAlD
Dasatinib—ZAK—lymph node—thyroid cancer	0.000288	0.0044	CbGeAlD
Dasatinib—CSF1R—trachea—thyroid cancer	0.000284	0.00434	CbGeAlD
Dasatinib—MAP4K5—thyroid gland—thyroid cancer	0.000282	0.0043	CbGeAlD
Dasatinib—MAP3K3—thyroid gland—thyroid cancer	0.000282	0.0043	CbGeAlD
Dasatinib—BMPR1B—lymph node—thyroid cancer	0.000276	0.00422	CbGeAlD
Dasatinib—MAPK14—head—thyroid cancer	0.000276	0.00421	CbGeAlD
Dasatinib—BTK—lymph node—thyroid cancer	0.000275	0.0042	CbGeAlD
Dasatinib—FGR—head—thyroid cancer	0.000275	0.00419	CbGeAlD
Dasatinib—TNK2—lymph node—thyroid cancer	0.000271	0.00414	CbGeAlD
Dasatinib—EPHB6—thyroid gland—thyroid cancer	0.00027	0.00411	CbGeAlD
Dasatinib—FMO3—head—thyroid cancer	0.000265	0.00405	CbGeAlD
Dasatinib—YES1—thyroid gland—thyroid cancer	0.00026	0.00397	CbGeAlD
Dasatinib—JAK2—head—thyroid cancer	0.00026	0.00396	CbGeAlD
Dasatinib—KIT—trachea—thyroid cancer	0.000258	0.00394	CbGeAlD
Dasatinib—EPHA2—head—thyroid cancer	0.000256	0.00391	CbGeAlD
Dasatinib—FYN—head—thyroid cancer	0.000256	0.00391	CbGeAlD
Dasatinib—PDGFRA—thyroid gland—thyroid cancer	0.000256	0.0039	CbGeAlD
Dasatinib—TESK1—lymph node—thyroid cancer	0.000255	0.00389	CbGeAlD
Dasatinib—CYP3A4—Doxorubicin—thyroid cancer	0.000254	0.000355	CbGbCtD
Dasatinib—PDGFRB—trachea—thyroid cancer	0.000252	0.00385	CbGeAlD
Dasatinib—STK36—lymph node—thyroid cancer	0.000251	0.00383	CbGeAlD
Dasatinib—EPHB3—lymph node—thyroid cancer	0.000251	0.00383	CbGeAlD
Dasatinib—SRC—thyroid gland—thyroid cancer	0.000251	0.00382	CbGeAlD
Dasatinib—MAP4K5—head—thyroid cancer	0.00025	0.00382	CbGeAlD
Dasatinib—MAP3K3—head—thyroid cancer	0.00025	0.00382	CbGeAlD
Dasatinib—LIMK2—lymph node—thyroid cancer	0.000242	0.0037	CbGeAlD
Dasatinib—EPHB6—head—thyroid cancer	0.000239	0.00365	CbGeAlD
Dasatinib—STK35—lymph node—thyroid cancer	0.000235	0.00359	CbGeAlD
Dasatinib—CSK—lymph node—thyroid cancer	0.000233	0.00356	CbGeAlD
Dasatinib—YES1—head—thyroid cancer	0.000231	0.00353	CbGeAlD
Dasatinib—MAP2K5—thyroid gland—thyroid cancer	0.000231	0.00352	CbGeAlD
Dasatinib—HCK—lymph node—thyroid cancer	0.00023	0.00352	CbGeAlD
Dasatinib—ABL2—lymph node—thyroid cancer	0.000229	0.00349	CbGeAlD
Dasatinib—PDGFRA—head—thyroid cancer	0.000227	0.00346	CbGeAlD
Dasatinib—CSF1R—thyroid gland—thyroid cancer	0.000225	0.00343	CbGeAlD
Dasatinib—ABL1—trachea—thyroid cancer	0.000225	0.00343	CbGeAlD
Dasatinib—SRC—head—thyroid cancer	0.000222	0.00339	CbGeAlD
Dasatinib—RIPK2—lymph node—thyroid cancer	0.000217	0.00331	CbGeAlD
Dasatinib—SIK1—lymph node—thyroid cancer	0.000212	0.00323	CbGeAlD
Dasatinib—EPHA4—lymph node—thyroid cancer	0.000209	0.0032	CbGeAlD
Dasatinib—ERBB3—lymph node—thyroid cancer	0.000207	0.00316	CbGeAlD
Dasatinib—MAP3K2—lymph node—thyroid cancer	0.000205	0.00313	CbGeAlD
Dasatinib—MAP2K5—head—thyroid cancer	0.000204	0.00312	CbGeAlD
Dasatinib—KIT—thyroid gland—thyroid cancer	0.000204	0.00312	CbGeAlD
Dasatinib—CSF1R—head—thyroid cancer	0.0002	0.00305	CbGeAlD
Dasatinib—PDGFRB—thyroid gland—thyroid cancer	0.0002	0.00304	CbGeAlD
Dasatinib—MAPK14—lymph node—thyroid cancer	0.000193	0.00295	CbGeAlD
Dasatinib—FGR—lymph node—thyroid cancer	0.000192	0.00293	CbGeAlD
Dasatinib—LCK—lymph node—thyroid cancer	0.000192	0.00293	CbGeAlD
Dasatinib—FMO3—lymph node—thyroid cancer	0.000186	0.00283	CbGeAlD
Dasatinib—ABCG2—saliva-secreting gland—thyroid cancer	0.000184	0.0028	CbGeAlD
Dasatinib—EPHB4—lymph node—thyroid cancer	0.000183	0.00279	CbGeAlD
Dasatinib—JAK2—lymph node—thyroid cancer	0.000182	0.00277	CbGeAlD
Dasatinib—KIT—head—thyroid cancer	0.000181	0.00277	CbGeAlD
Dasatinib—EPHA2—lymph node—thyroid cancer	0.00018	0.00274	CbGeAlD
Dasatinib—FYN—lymph node—thyroid cancer	0.000179	0.00274	CbGeAlD
Dasatinib—CSK—Doxorubicin—Epirubicin—thyroid cancer	0.000178	0.0732	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Epirubicin—thyroid cancer	0.000178	0.0732	CbGdCrCtD
Dasatinib—ABL1—thyroid gland—thyroid cancer	0.000178	0.00271	CbGeAlD
Dasatinib—PDGFRB—head—thyroid cancer	0.000177	0.0027	CbGeAlD
Dasatinib—MAP3K3—lymph node—thyroid cancer	0.000175	0.00267	CbGeAlD
Dasatinib—MAP4K5—lymph node—thyroid cancer	0.000175	0.00267	CbGeAlD
Dasatinib—EPHB6—lymph node—thyroid cancer	0.000167	0.00256	CbGeAlD
Dasatinib—CSK—Epirubicin—Doxorubicin—thyroid cancer	0.000165	0.0677	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Doxorubicin—thyroid cancer	0.000165	0.0677	CbGdCrCtD
Dasatinib—YES1—lymph node—thyroid cancer	0.000162	0.00247	CbGeAlD
Dasatinib—PDGFRA—lymph node—thyroid cancer	0.000159	0.00242	CbGeAlD
Dasatinib—ABL1—head—thyroid cancer	0.000158	0.00241	CbGeAlD
Dasatinib—SRC—lymph node—thyroid cancer	0.000156	0.00238	CbGeAlD
Dasatinib—CYP1B1—thyroid gland—thyroid cancer	0.000151	0.0023	CbGeAlD
Dasatinib—MAP2K5—lymph node—thyroid cancer	0.000143	0.00219	CbGeAlD
Dasatinib—CSF1R—lymph node—thyroid cancer	0.00014	0.00213	CbGeAlD
Dasatinib—CYP1A1—trachea—thyroid cancer	0.000135	0.00205	CbGeAlD
Dasatinib—CYP1B1—head—thyroid cancer	0.000134	0.00204	CbGeAlD
Dasatinib—KIT—lymph node—thyroid cancer	0.000127	0.00194	CbGeAlD
Dasatinib—ABL1—Doxorubicin—Epirubicin—thyroid cancer	0.000124	0.0511	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Epirubicin—thyroid cancer	0.000124	0.0511	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Epirubicin—thyroid cancer	0.000124	0.0511	CbGdCrCtD
Dasatinib—PDGFRB—lymph node—thyroid cancer	0.000124	0.00189	CbGeAlD
Dasatinib—ABL1—Epirubicin—Doxorubicin—thyroid cancer	0.000115	0.0473	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Doxorubicin—thyroid cancer	0.000115	0.0473	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—thyroid cancer	0.000115	0.0473	CbGdCrCtD
Dasatinib—ABCG2—thyroid gland—thyroid cancer	0.000112	0.00171	CbGeAlD
Dasatinib—ABL1—lymph node—thyroid cancer	0.00011	0.00169	CbGeAlD
Dasatinib—CYP1A2—thyroid gland—thyroid cancer	0.000108	0.00165	CbGeAlD
Dasatinib—CYP1A1—thyroid gland—thyroid cancer	0.000106	0.00162	CbGeAlD
Dasatinib—Fatigue—Sorafenib—thyroid cancer	9.62e-05	0.000907	CcSEcCtD
Dasatinib—Photosensitivity—Epirubicin—thyroid cancer	9.55e-05	0.000901	CcSEcCtD
Dasatinib—Pain—Sorafenib—thyroid cancer	9.54e-05	0.000899	CcSEcCtD
Dasatinib—Constipation—Sorafenib—thyroid cancer	9.54e-05	0.000899	CcSEcCtD
Dasatinib—Pulmonary oedema—Doxorubicin—thyroid cancer	9.52e-05	0.000897	CcSEcCtD
Dasatinib—CYP1A1—head—thyroid cancer	9.44e-05	0.00144	CbGeAlD
Dasatinib—CYP1B1—lymph node—thyroid cancer	9.35e-05	0.00143	CbGeAlD
Dasatinib—Eczema—Epirubicin—thyroid cancer	9.33e-05	0.00088	CcSEcCtD
Dasatinib—Sepsis—Doxorubicin—thyroid cancer	9.28e-05	0.000875	CcSEcCtD
Dasatinib—Cardiac failure congestive—Epirubicin—thyroid cancer	9.25e-05	0.000872	CcSEcCtD
Dasatinib—Gastrointestinal pain—Sorafenib—thyroid cancer	9.12e-05	0.00086	CcSEcCtD
Dasatinib—Thrombophlebitis—Doxorubicin—thyroid cancer	8.97e-05	0.000845	CcSEcCtD
Dasatinib—Urticaria—Sorafenib—thyroid cancer	8.86e-05	0.000835	CcSEcCtD
Dasatinib—Photosensitivity—Doxorubicin—thyroid cancer	8.84e-05	0.000833	CcSEcCtD
Dasatinib—Abdominal pain—Sorafenib—thyroid cancer	8.82e-05	0.000831	CcSEcCtD
Dasatinib—Body temperature increased—Sorafenib—thyroid cancer	8.82e-05	0.000831	CcSEcCtD
Dasatinib—Eczema—Doxorubicin—thyroid cancer	8.64e-05	0.000814	CcSEcCtD
Dasatinib—Cardiac failure—Epirubicin—thyroid cancer	8.6e-05	0.00081	CcSEcCtD
Dasatinib—Cerebrovascular accident—Epirubicin—thyroid cancer	8.56e-05	0.000807	CcSEcCtD
Dasatinib—Cardiac failure congestive—Doxorubicin—thyroid cancer	8.56e-05	0.000807	CcSEcCtD
Dasatinib—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	8.39e-05	0.000791	CcSEcCtD
Dasatinib—Affect lability—Epirubicin—thyroid cancer	8.26e-05	0.000778	CcSEcCtD
Dasatinib—Hypersensitivity—Sorafenib—thyroid cancer	8.22e-05	0.000775	CcSEcCtD
Dasatinib—Face oedema—Epirubicin—thyroid cancer	8.1e-05	0.000763	CcSEcCtD
Dasatinib—Asthenia—Sorafenib—thyroid cancer	8e-05	0.000755	CcSEcCtD
Dasatinib—Cardiac failure—Doxorubicin—thyroid cancer	7.95e-05	0.00075	CcSEcCtD
Dasatinib—Cerebrovascular accident—Doxorubicin—thyroid cancer	7.92e-05	0.000747	CcSEcCtD
Dasatinib—Pruritus—Sorafenib—thyroid cancer	7.89e-05	0.000744	CcSEcCtD
Dasatinib—Blood creatinine increased—Epirubicin—thyroid cancer	7.86e-05	0.000741	CcSEcCtD
Dasatinib—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	7.76e-05	0.000732	CcSEcCtD
Dasatinib—Dry skin—Epirubicin—thyroid cancer	7.69e-05	0.000725	CcSEcCtD
Dasatinib—Affect lability—Doxorubicin—thyroid cancer	7.64e-05	0.00072	CcSEcCtD
Dasatinib—Hypokalaemia—Epirubicin—thyroid cancer	7.63e-05	0.00072	CcSEcCtD
Dasatinib—Diarrhoea—Sorafenib—thyroid cancer	7.63e-05	0.00072	CcSEcCtD
Dasatinib—Breast disorder—Epirubicin—thyroid cancer	7.58e-05	0.000715	CcSEcCtD
Dasatinib—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	7.55e-05	0.000712	CcSEcCtD
Dasatinib—Face oedema—Doxorubicin—thyroid cancer	7.49e-05	0.000706	CcSEcCtD
Dasatinib—Gastritis—Epirubicin—thyroid cancer	7.42e-05	0.0007	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	7.4e-05	0.000697	CcSEcCtD
Dasatinib—Muscular weakness—Epirubicin—thyroid cancer	7.4e-05	0.000697	CcSEcCtD
Dasatinib—Dizziness—Sorafenib—thyroid cancer	7.38e-05	0.000695	CcSEcCtD
Dasatinib—Abdominal distension—Epirubicin—thyroid cancer	7.3e-05	0.000688	CcSEcCtD
Dasatinib—Blood creatinine increased—Doxorubicin—thyroid cancer	7.27e-05	0.000685	CcSEcCtD
Dasatinib—Asthma—Epirubicin—thyroid cancer	7.25e-05	0.000683	CcSEcCtD
Dasatinib—Dysphagia—Epirubicin—thyroid cancer	7.25e-05	0.000683	CcSEcCtD
Dasatinib—Dry skin—Doxorubicin—thyroid cancer	7.11e-05	0.000671	CcSEcCtD
Dasatinib—Pancreatitis—Epirubicin—thyroid cancer	7.11e-05	0.00067	CcSEcCtD
Dasatinib—Vomiting—Sorafenib—thyroid cancer	7.09e-05	0.000669	CcSEcCtD
Dasatinib—Hypokalaemia—Doxorubicin—thyroid cancer	7.06e-05	0.000666	CcSEcCtD
Dasatinib—Angina pectoris—Epirubicin—thyroid cancer	7.06e-05	0.000666	CcSEcCtD
Dasatinib—Rash—Sorafenib—thyroid cancer	7.03e-05	0.000663	CcSEcCtD
Dasatinib—Dermatitis—Sorafenib—thyroid cancer	7.03e-05	0.000662	CcSEcCtD
Dasatinib—Breast disorder—Doxorubicin—thyroid cancer	7.01e-05	0.000661	CcSEcCtD
Dasatinib—ABCB1—trachea—thyroid cancer	6.99e-05	0.00107	CbGeAlD
Dasatinib—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	6.99e-05	0.000659	CcSEcCtD
Dasatinib—Headache—Sorafenib—thyroid cancer	6.99e-05	0.000659	CcSEcCtD
Dasatinib—ABCG2—lymph node—thyroid cancer	6.97e-05	0.00106	CbGeAlD
Dasatinib—Pancytopenia—Epirubicin—thyroid cancer	6.89e-05	0.000649	CcSEcCtD
Dasatinib—Gastritis—Doxorubicin—thyroid cancer	6.87e-05	0.000648	CcSEcCtD
Dasatinib—Muscular weakness—Doxorubicin—thyroid cancer	6.85e-05	0.000645	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	6.85e-05	0.000645	CcSEcCtD
Dasatinib—Neutropenia—Epirubicin—thyroid cancer	6.78e-05	0.000639	CcSEcCtD
Dasatinib—Abdominal distension—Doxorubicin—thyroid cancer	6.75e-05	0.000637	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Epirubicin—thyroid cancer	6.74e-05	0.000635	CcSEcCtD
Dasatinib—Asthma—Doxorubicin—thyroid cancer	6.71e-05	0.000632	CcSEcCtD
Dasatinib—Dysphagia—Doxorubicin—thyroid cancer	6.71e-05	0.000632	CcSEcCtD
Dasatinib—Pollakiuria—Epirubicin—thyroid cancer	6.7e-05	0.000631	CcSEcCtD
Dasatinib—Nausea—Sorafenib—thyroid cancer	6.63e-05	0.000625	CcSEcCtD
Dasatinib—Photosensitivity reaction—Epirubicin—thyroid cancer	6.62e-05	0.000624	CcSEcCtD
Dasatinib—CYP1A1—lymph node—thyroid cancer	6.61e-05	0.00101	CbGeAlD
Dasatinib—Weight increased—Epirubicin—thyroid cancer	6.6e-05	0.000622	CcSEcCtD
Dasatinib—Pancreatitis—Doxorubicin—thyroid cancer	6.58e-05	0.00062	CcSEcCtD
Dasatinib—Weight decreased—Epirubicin—thyroid cancer	6.56e-05	0.000618	CcSEcCtD
Dasatinib—Angina pectoris—Doxorubicin—thyroid cancer	6.53e-05	0.000616	CcSEcCtD
Dasatinib—Pneumonia—Epirubicin—thyroid cancer	6.5e-05	0.000613	CcSEcCtD
Dasatinib—Infestation NOS—Epirubicin—thyroid cancer	6.46e-05	0.000609	CcSEcCtD
Dasatinib—Infestation—Epirubicin—thyroid cancer	6.46e-05	0.000609	CcSEcCtD
Dasatinib—Pancytopenia—Doxorubicin—thyroid cancer	6.37e-05	0.000601	CcSEcCtD
Dasatinib—Renal failure—Epirubicin—thyroid cancer	6.35e-05	0.000599	CcSEcCtD
Dasatinib—Neuropathy peripheral—Epirubicin—thyroid cancer	6.34e-05	0.000597	CcSEcCtD
Dasatinib—Stomatitis—Epirubicin—thyroid cancer	6.3e-05	0.000594	CcSEcCtD
Dasatinib—Conjunctivitis—Epirubicin—thyroid cancer	6.28e-05	0.000592	CcSEcCtD
Dasatinib—Neutropenia—Doxorubicin—thyroid cancer	6.27e-05	0.000591	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Doxorubicin—thyroid cancer	6.24e-05	0.000588	CcSEcCtD
Dasatinib—Pollakiuria—Doxorubicin—thyroid cancer	6.2e-05	0.000584	CcSEcCtD
Dasatinib—Haematuria—Epirubicin—thyroid cancer	6.16e-05	0.000581	CcSEcCtD
Dasatinib—Photosensitivity reaction—Doxorubicin—thyroid cancer	6.12e-05	0.000577	CcSEcCtD
Dasatinib—Hepatobiliary disease—Epirubicin—thyroid cancer	6.11e-05	0.000576	CcSEcCtD
Dasatinib—Weight increased—Doxorubicin—thyroid cancer	6.11e-05	0.000576	CcSEcCtD
Dasatinib—Epistaxis—Epirubicin—thyroid cancer	6.1e-05	0.000575	CcSEcCtD
Dasatinib—Weight decreased—Doxorubicin—thyroid cancer	6.07e-05	0.000572	CcSEcCtD
Dasatinib—Pneumonia—Doxorubicin—thyroid cancer	6.02e-05	0.000567	CcSEcCtD
Dasatinib—Infestation NOS—Doxorubicin—thyroid cancer	5.98e-05	0.000564	CcSEcCtD
Dasatinib—Infestation—Doxorubicin—thyroid cancer	5.98e-05	0.000564	CcSEcCtD
Dasatinib—Renal failure—Doxorubicin—thyroid cancer	5.88e-05	0.000554	CcSEcCtD
Dasatinib—Neuropathy peripheral—Doxorubicin—thyroid cancer	5.86e-05	0.000553	CcSEcCtD
Dasatinib—Haemoglobin—Epirubicin—thyroid cancer	5.83e-05	0.00055	CcSEcCtD
Dasatinib—Stomatitis—Doxorubicin—thyroid cancer	5.83e-05	0.00055	CcSEcCtD
Dasatinib—Conjunctivitis—Doxorubicin—thyroid cancer	5.81e-05	0.000548	CcSEcCtD
Dasatinib—Hepatitis—Epirubicin—thyroid cancer	5.8e-05	0.000547	CcSEcCtD
Dasatinib—Haemorrhage—Epirubicin—thyroid cancer	5.8e-05	0.000547	CcSEcCtD
Dasatinib—Urinary tract disorder—Epirubicin—thyroid cancer	5.73e-05	0.00054	CcSEcCtD
Dasatinib—Oedema peripheral—Epirubicin—thyroid cancer	5.72e-05	0.000539	CcSEcCtD
Dasatinib—Haematuria—Doxorubicin—thyroid cancer	5.7e-05	0.000538	CcSEcCtD
Dasatinib—Connective tissue disorder—Epirubicin—thyroid cancer	5.7e-05	0.000538	CcSEcCtD
Dasatinib—Urethral disorder—Epirubicin—thyroid cancer	5.69e-05	0.000536	CcSEcCtD
Dasatinib—Hepatobiliary disease—Doxorubicin—thyroid cancer	5.66e-05	0.000533	CcSEcCtD
Dasatinib—Epistaxis—Doxorubicin—thyroid cancer	5.64e-05	0.000532	CcSEcCtD
Dasatinib—Visual impairment—Epirubicin—thyroid cancer	5.59e-05	0.000527	CcSEcCtD
Dasatinib—ABCB1—thyroid gland—thyroid cancer	5.53e-05	0.000844	CbGeAlD
Dasatinib—Erythema multiforme—Epirubicin—thyroid cancer	5.49e-05	0.000517	CcSEcCtD
Dasatinib—Eye disorder—Epirubicin—thyroid cancer	5.42e-05	0.000511	CcSEcCtD
Dasatinib—Tinnitus—Epirubicin—thyroid cancer	5.41e-05	0.00051	CcSEcCtD
Dasatinib—Haemoglobin—Doxorubicin—thyroid cancer	5.4e-05	0.000509	CcSEcCtD
Dasatinib—Flushing—Epirubicin—thyroid cancer	5.39e-05	0.000508	CcSEcCtD
Dasatinib—Cardiac disorder—Epirubicin—thyroid cancer	5.39e-05	0.000508	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—thyroid cancer	5.37e-05	0.000506	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—thyroid cancer	5.37e-05	0.000506	CcSEcCtD
Dasatinib—Urinary tract disorder—Doxorubicin—thyroid cancer	5.3e-05	0.0005	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—thyroid cancer	5.29e-05	0.000499	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—thyroid cancer	5.28e-05	0.000497	CcSEcCtD
Dasatinib—Angiopathy—Epirubicin—thyroid cancer	5.27e-05	0.000496	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—thyroid cancer	5.26e-05	0.000496	CcSEcCtD
Dasatinib—Immune system disorder—Epirubicin—thyroid cancer	5.24e-05	0.000494	CcSEcCtD
Dasatinib—Mediastinal disorder—Epirubicin—thyroid cancer	5.23e-05	0.000493	CcSEcCtD
Dasatinib—Chills—Epirubicin—thyroid cancer	5.21e-05	0.000491	CcSEcCtD
Dasatinib—Arrhythmia—Epirubicin—thyroid cancer	5.18e-05	0.000489	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—thyroid cancer	5.17e-05	0.000488	CcSEcCtD
Dasatinib—Alopecia—Epirubicin—thyroid cancer	5.13e-05	0.000483	CcSEcCtD
Dasatinib—Mental disorder—Epirubicin—thyroid cancer	5.08e-05	0.000479	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—thyroid cancer	5.08e-05	0.000479	CcSEcCtD
Dasatinib—Erythema—Epirubicin—thyroid cancer	5.05e-05	0.000476	CcSEcCtD
Dasatinib—Malnutrition—Epirubicin—thyroid cancer	5.05e-05	0.000476	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—thyroid cancer	5.02e-05	0.000473	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—thyroid cancer	5.01e-05	0.000472	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—thyroid cancer	4.98e-05	0.00047	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—thyroid cancer	4.98e-05	0.00047	CcSEcCtD
Dasatinib—Dysgeusia—Epirubicin—thyroid cancer	4.95e-05	0.000466	CcSEcCtD
Dasatinib—ABCB1—head—thyroid cancer	4.91e-05	0.000749	CbGeAlD
Dasatinib—Angiopathy—Doxorubicin—thyroid cancer	4.87e-05	0.000459	CcSEcCtD
Dasatinib—Muscle spasms—Epirubicin—thyroid cancer	4.86e-05	0.000458	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—thyroid cancer	4.85e-05	0.000457	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—thyroid cancer	4.84e-05	0.000456	CcSEcCtD
Dasatinib—Chills—Doxorubicin—thyroid cancer	4.82e-05	0.000454	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—thyroid cancer	4.8e-05	0.000452	CcSEcCtD
Dasatinib—Vision blurred—Epirubicin—thyroid cancer	4.76e-05	0.000449	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—thyroid cancer	4.75e-05	0.000447	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—thyroid cancer	4.7e-05	0.000443	CcSEcCtD
Dasatinib—Ill-defined disorder—Epirubicin—thyroid cancer	4.69e-05	0.000442	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—thyroid cancer	4.67e-05	0.000441	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—thyroid cancer	4.67e-05	0.000441	CcSEcCtD
Dasatinib—Anaemia—Epirubicin—thyroid cancer	4.67e-05	0.00044	CcSEcCtD
Dasatinib—Dysgeusia—Doxorubicin—thyroid cancer	4.58e-05	0.000432	CcSEcCtD
Dasatinib—Malaise—Epirubicin—thyroid cancer	4.56e-05	0.000429	CcSEcCtD
Dasatinib—Vertigo—Epirubicin—thyroid cancer	4.54e-05	0.000428	CcSEcCtD
Dasatinib—Syncope—Epirubicin—thyroid cancer	4.53e-05	0.000427	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—thyroid cancer	4.49e-05	0.000424	CcSEcCtD
Dasatinib—Palpitations—Epirubicin—thyroid cancer	4.46e-05	0.000421	CcSEcCtD
Dasatinib—Loss of consciousness—Epirubicin—thyroid cancer	4.44e-05	0.000419	CcSEcCtD
Dasatinib—Cough—Epirubicin—thyroid cancer	4.41e-05	0.000416	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—thyroid cancer	4.41e-05	0.000415	CcSEcCtD
Dasatinib—Convulsion—Epirubicin—thyroid cancer	4.38e-05	0.000413	CcSEcCtD
Dasatinib—Hypertension—Epirubicin—thyroid cancer	4.36e-05	0.000411	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—thyroid cancer	4.34e-05	0.000409	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—thyroid cancer	4.32e-05	0.000407	CcSEcCtD
Dasatinib—Myalgia—Epirubicin—thyroid cancer	4.3e-05	0.000405	CcSEcCtD
Dasatinib—Chest pain—Epirubicin—thyroid cancer	4.3e-05	0.000405	CcSEcCtD
Dasatinib—Arthralgia—Epirubicin—thyroid cancer	4.3e-05	0.000405	CcSEcCtD
Dasatinib—Anxiety—Epirubicin—thyroid cancer	4.29e-05	0.000404	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	4.27e-05	0.000403	CcSEcCtD
Dasatinib—Discomfort—Epirubicin—thyroid cancer	4.25e-05	0.000401	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—thyroid cancer	4.22e-05	0.000397	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—thyroid cancer	4.2e-05	0.000396	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—thyroid cancer	4.19e-05	0.000395	CcSEcCtD
Dasatinib—Confusional state—Epirubicin—thyroid cancer	4.16e-05	0.000392	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—thyroid cancer	4.13e-05	0.000389	CcSEcCtD
Dasatinib—Oedema—Epirubicin—thyroid cancer	4.12e-05	0.000389	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—thyroid cancer	4.11e-05	0.000387	CcSEcCtD
Dasatinib—Infection—Epirubicin—thyroid cancer	4.1e-05	0.000386	CcSEcCtD
Dasatinib—Cough—Doxorubicin—thyroid cancer	4.08e-05	0.000385	CcSEcCtD
Dasatinib—Shock—Epirubicin—thyroid cancer	4.06e-05	0.000382	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—thyroid cancer	4.05e-05	0.000382	CcSEcCtD
Dasatinib—Nervous system disorder—Epirubicin—thyroid cancer	4.04e-05	0.000381	CcSEcCtD
Dasatinib—Thrombocytopenia—Epirubicin—thyroid cancer	4.04e-05	0.000381	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—thyroid cancer	4.04e-05	0.00038	CcSEcCtD
Dasatinib—Tachycardia—Epirubicin—thyroid cancer	4.02e-05	0.000379	CcSEcCtD
Dasatinib—Skin disorder—Epirubicin—thyroid cancer	4e-05	0.000378	CcSEcCtD
Dasatinib—Hyperhidrosis—Epirubicin—thyroid cancer	3.99e-05	0.000376	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—thyroid cancer	3.98e-05	0.000375	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—thyroid cancer	3.98e-05	0.000375	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—thyroid cancer	3.98e-05	0.000375	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—thyroid cancer	3.97e-05	0.000374	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	3.95e-05	0.000373	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—thyroid cancer	3.93e-05	0.000371	CcSEcCtD
Dasatinib—Anorexia—Epirubicin—thyroid cancer	3.93e-05	0.00037	CcSEcCtD
Dasatinib—Hypotension—Epirubicin—thyroid cancer	3.85e-05	0.000363	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—thyroid cancer	3.85e-05	0.000363	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—thyroid cancer	3.81e-05	0.00036	CcSEcCtD
Dasatinib—Infection—Doxorubicin—thyroid cancer	3.79e-05	0.000357	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Epirubicin—thyroid cancer	3.76e-05	0.000354	CcSEcCtD
Dasatinib—Shock—Doxorubicin—thyroid cancer	3.75e-05	0.000354	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—thyroid cancer	3.74e-05	0.000353	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—thyroid cancer	3.74e-05	0.000352	CcSEcCtD
Dasatinib—Insomnia—Epirubicin—thyroid cancer	3.73e-05	0.000352	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—thyroid cancer	3.72e-05	0.000351	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—thyroid cancer	3.71e-05	0.000349	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—thyroid cancer	3.69e-05	0.000348	CcSEcCtD
Dasatinib—Dyspnoea—Epirubicin—thyroid cancer	3.68e-05	0.000347	CcSEcCtD
Dasatinib—Somnolence—Epirubicin—thyroid cancer	3.67e-05	0.000346	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—thyroid cancer	3.64e-05	0.000343	CcSEcCtD
Dasatinib—Dyspepsia—Epirubicin—thyroid cancer	3.63e-05	0.000342	CcSEcCtD
Dasatinib—Decreased appetite—Epirubicin—thyroid cancer	3.58e-05	0.000338	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—thyroid cancer	3.56e-05	0.000336	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Epirubicin—thyroid cancer	3.56e-05	0.000336	CcSEcCtD
Dasatinib—Fatigue—Epirubicin—thyroid cancer	3.55e-05	0.000335	CcSEcCtD
Dasatinib—Constipation—Epirubicin—thyroid cancer	3.53e-05	0.000332	CcSEcCtD
Dasatinib—Pain—Epirubicin—thyroid cancer	3.53e-05	0.000332	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	3.48e-05	0.000328	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—thyroid cancer	3.45e-05	0.000325	CcSEcCtD
Dasatinib—ABCB1—lymph node—thyroid cancer	3.44e-05	0.000524	CbGeAlD
Dasatinib—Dyspnoea—Doxorubicin—thyroid cancer	3.4e-05	0.000321	CcSEcCtD
Dasatinib—Feeling abnormal—Epirubicin—thyroid cancer	3.4e-05	0.00032	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—thyroid cancer	3.39e-05	0.00032	CcSEcCtD
Dasatinib—Gastrointestinal pain—Epirubicin—thyroid cancer	3.37e-05	0.000318	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—thyroid cancer	3.36e-05	0.000317	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—thyroid cancer	3.32e-05	0.000313	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	3.29e-05	0.00031	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—thyroid cancer	3.29e-05	0.00031	CcSEcCtD
Dasatinib—Urticaria—Epirubicin—thyroid cancer	3.28e-05	0.000309	CcSEcCtD
Dasatinib—Pain—Doxorubicin—thyroid cancer	3.26e-05	0.000308	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—thyroid cancer	3.26e-05	0.000308	CcSEcCtD
Dasatinib—Body temperature increased—Epirubicin—thyroid cancer	3.26e-05	0.000307	CcSEcCtD
Dasatinib—Abdominal pain—Epirubicin—thyroid cancer	3.26e-05	0.000307	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—thyroid cancer	3.14e-05	0.000296	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—thyroid cancer	3.12e-05	0.000294	CcSEcCtD
Dasatinib—Hypersensitivity—Epirubicin—thyroid cancer	3.04e-05	0.000286	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—thyroid cancer	3.03e-05	0.000286	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—thyroid cancer	3.02e-05	0.000284	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—thyroid cancer	3.02e-05	0.000284	CcSEcCtD
Dasatinib—Asthenia—Epirubicin—thyroid cancer	2.96e-05	0.000279	CcSEcCtD
Dasatinib—Pruritus—Epirubicin—thyroid cancer	2.92e-05	0.000275	CcSEcCtD
Dasatinib—Diarrhoea—Epirubicin—thyroid cancer	2.82e-05	0.000266	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—thyroid cancer	2.81e-05	0.000265	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—thyroid cancer	2.74e-05	0.000258	CcSEcCtD
Dasatinib—Dizziness—Epirubicin—thyroid cancer	2.73e-05	0.000257	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—thyroid cancer	2.7e-05	0.000254	CcSEcCtD
Dasatinib—Vomiting—Epirubicin—thyroid cancer	2.62e-05	0.000247	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—thyroid cancer	2.61e-05	0.000246	CcSEcCtD
Dasatinib—Rash—Epirubicin—thyroid cancer	2.6e-05	0.000245	CcSEcCtD
Dasatinib—Dermatitis—Epirubicin—thyroid cancer	2.6e-05	0.000245	CcSEcCtD
Dasatinib—Headache—Epirubicin—thyroid cancer	2.58e-05	0.000243	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—thyroid cancer	2.52e-05	0.000238	CcSEcCtD
Dasatinib—Nausea—Epirubicin—thyroid cancer	2.45e-05	0.000231	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—thyroid cancer	2.43e-05	0.000229	CcSEcCtD
Dasatinib—Rash—Doxorubicin—thyroid cancer	2.41e-05	0.000227	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—thyroid cancer	2.4e-05	0.000227	CcSEcCtD
Dasatinib—Headache—Doxorubicin—thyroid cancer	2.39e-05	0.000225	CcSEcCtD
Dasatinib—Nausea—Doxorubicin—thyroid cancer	2.27e-05	0.000214	CcSEcCtD
Dasatinib—BLK—Immune System—AKT1—thyroid cancer	2.05e-06	1.87e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—RXRA—thyroid cancer	2.05e-06	1.87e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—AKT1—thyroid cancer	2.04e-06	1.87e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	2.04e-06	1.86e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—KRAS—thyroid cancer	2.04e-06	1.86e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—BRAF—thyroid cancer	2.03e-06	1.85e-05	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—AKT1—thyroid cancer	2.03e-06	1.85e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TERT—thyroid cancer	2.03e-06	1.85e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—PTEN—thyroid cancer	2.02e-06	1.85e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—thyroid cancer	2.01e-06	1.84e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—PTEN—thyroid cancer	2.01e-06	1.84e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—AKT1—thyroid cancer	2e-06	1.83e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—BRAF—thyroid cancer	2e-06	1.83e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NRG1—thyroid cancer	2e-06	1.82e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—PTEN—thyroid cancer	2e-06	1.82e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—AKT1—thyroid cancer	2e-06	1.82e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—NRAS—thyroid cancer	1.99e-06	1.82e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.99e-06	1.82e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—AKT1—thyroid cancer	1.98e-06	1.8e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—HRAS—thyroid cancer	1.96e-06	1.79e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—HRAS—thyroid cancer	1.96e-06	1.79e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—KRAS—thyroid cancer	1.96e-06	1.79e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—KRAS—thyroid cancer	1.96e-06	1.79e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—HRAS—thyroid cancer	1.96e-06	1.79e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—BRAF—thyroid cancer	1.96e-06	1.79e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—NRAS—thyroid cancer	1.95e-06	1.78e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—NRAS—thyroid cancer	1.95e-06	1.78e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.95e-06	1.78e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—NRAS—thyroid cancer	1.94e-06	1.78e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—PTEN—thyroid cancer	1.94e-06	1.77e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HIF1A—thyroid cancer	1.94e-06	1.77e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—BRAF—thyroid cancer	1.93e-06	1.76e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—HRAS—thyroid cancer	1.93e-06	1.76e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—AKT1—thyroid cancer	1.92e-06	1.75e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CCND1—thyroid cancer	1.92e-06	1.75e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PPARG—thyroid cancer	1.91e-06	1.74e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—AKT1—thyroid cancer	1.91e-06	1.74e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—NRAS—thyroid cancer	1.9e-06	1.74e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—NRAS—thyroid cancer	1.89e-06	1.73e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—HRAS—thyroid cancer	1.88e-06	1.72e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—NRAS—thyroid cancer	1.88e-06	1.72e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—AKT1—thyroid cancer	1.88e-06	1.72e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—NRAS—thyroid cancer	1.87e-06	1.71e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—HRAS—thyroid cancer	1.87e-06	1.71e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—KRAS—thyroid cancer	1.86e-06	1.7e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—BRAF—thyroid cancer	1.86e-06	1.69e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—PTGS2—thyroid cancer	1.85e-06	1.69e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.85e-06	1.69e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PTEN—thyroid cancer	1.85e-06	1.69e-05	CbGpPWpGaD
Dasatinib—FMO3—Metabolism—AKT1—thyroid cancer	1.85e-06	1.69e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—AKT1—thyroid cancer	1.85e-06	1.68e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—PTEN—thyroid cancer	1.84e-06	1.68e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—KRAS—thyroid cancer	1.84e-06	1.68e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—BRAF—thyroid cancer	1.83e-06	1.67e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—KRAS—thyroid cancer	1.81e-06	1.65e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—NRAS—thyroid cancer	1.8e-06	1.65e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—NRAS—thyroid cancer	1.79e-06	1.64e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TERT—thyroid cancer	1.79e-06	1.64e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—NRAS—thyroid cancer	1.78e-06	1.63e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—PTEN—thyroid cancer	1.75e-06	1.6e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—HRAS—thyroid cancer	1.73e-06	1.58e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—AKT1—thyroid cancer	1.73e-06	1.58e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—AKT1—thyroid cancer	1.73e-06	1.58e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—AKT1—thyroid cancer	1.73e-06	1.58e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—NRAS—thyroid cancer	1.73e-06	1.58e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HIF1A—thyroid cancer	1.72e-06	1.57e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—KRAS—thyroid cancer	1.71e-06	1.57e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CCND1—thyroid cancer	1.71e-06	1.56e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—AKT1—thyroid cancer	1.7e-06	1.55e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—KRAS—thyroid cancer	1.68e-06	1.53e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—KRAS—thyroid cancer	1.68e-06	1.53e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—KRAS—thyroid cancer	1.67e-06	1.53e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—HRAS—thyroid cancer	1.67e-06	1.52e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—HRAS—thyroid cancer	1.67e-06	1.52e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—AKT1—thyroid cancer	1.66e-06	1.52e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PTEN—thyroid cancer	1.65e-06	1.51e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PTGS2—thyroid cancer	1.65e-06	1.51e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—NRAS—thyroid cancer	1.65e-06	1.51e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—AKT1—thyroid cancer	1.65e-06	1.51e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—NRAS—thyroid cancer	1.64e-06	1.5e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—PTGS2—thyroid cancer	1.64e-06	1.5e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—KRAS—thyroid cancer	1.64e-06	1.5e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—RXRA—thyroid cancer	1.63e-06	1.49e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—thyroid cancer	1.63e-06	1.49e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—KRAS—thyroid cancer	1.63e-06	1.49e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CCND1—thyroid cancer	1.62e-06	1.48e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—KRAS—thyroid cancer	1.62e-06	1.48e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—PTEN—thyroid cancer	1.61e-06	1.47e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—KRAS—thyroid cancer	1.61e-06	1.47e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—BRAF—thyroid cancer	1.61e-06	1.47e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TPR—thyroid cancer	1.6e-06	1.46e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—HRAS—thyroid cancer	1.58e-06	1.44e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.58e-06	1.44e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PTEN—thyroid cancer	1.56e-06	1.43e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—HRAS—thyroid cancer	1.56e-06	1.42e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—NRAS—thyroid cancer	1.56e-06	1.42e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—KRAS—thyroid cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—PTEN—thyroid cancer	1.55e-06	1.41e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—KRAS—thyroid cancer	1.54e-06	1.41e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—HRAS—thyroid cancer	1.54e-06	1.41e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—KRAS—thyroid cancer	1.53e-06	1.4e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—AKT1—thyroid cancer	1.53e-06	1.4e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTGS2—thyroid cancer	1.5e-06	1.37e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—thyroid cancer	1.49e-06	1.36e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—KRAS—thyroid cancer	1.49e-06	1.36e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—NRAS—thyroid cancer	1.47e-06	1.35e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—AKT1—thyroid cancer	1.47e-06	1.34e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—AKT1—thyroid cancer	1.47e-06	1.34e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CCND1—thyroid cancer	1.46e-06	1.33e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—HRAS—thyroid cancer	1.46e-06	1.33e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.46e-06	1.33e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—NRAS—thyroid cancer	1.44e-06	1.32e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PTEN—thyroid cancer	1.44e-06	1.31e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—thyroid cancer	1.44e-06	1.31e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—PTEN—thyroid cancer	1.43e-06	1.31e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CCND1—thyroid cancer	1.43e-06	1.3e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—HRAS—thyroid cancer	1.43e-06	1.3e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—HRAS—thyroid cancer	1.43e-06	1.3e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—HRAS—thyroid cancer	1.42e-06	1.3e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—BRAF—thyroid cancer	1.42e-06	1.3e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—KRAS—thyroid cancer	1.42e-06	1.3e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—KRAS—thyroid cancer	1.42e-06	1.29e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PTEN—thyroid cancer	1.41e-06	1.29e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCND1—thyroid cancer	1.41e-06	1.28e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NRAS—thyroid cancer	1.4e-06	1.27e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—AKT1—thyroid cancer	1.39e-06	1.27e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—HRAS—thyroid cancer	1.39e-06	1.27e-05	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—AKT1—thyroid cancer	1.39e-06	1.27e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—HRAS—thyroid cancer	1.39e-06	1.27e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—NRAS—thyroid cancer	1.38e-06	1.26e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PTEN—thyroid cancer	1.38e-06	1.26e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—AKT1—thyroid cancer	1.38e-06	1.26e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—HRAS—thyroid cancer	1.38e-06	1.26e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—HRAS—thyroid cancer	1.37e-06	1.25e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PPARG—thyroid cancer	1.37e-06	1.25e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—AKT1—thyroid cancer	1.36e-06	1.24e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PTEN—thyroid cancer	1.36e-06	1.24e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCND1—thyroid cancer	1.35e-06	1.24e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—KRAS—thyroid cancer	1.34e-06	1.23e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCND1—thyroid cancer	1.34e-06	1.22e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—thyroid cancer	1.32e-06	1.21e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—thyroid cancer	1.31e-06	1.2e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTEN—thyroid cancer	1.31e-06	1.2e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PTEN—thyroid cancer	1.31e-06	1.19e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—RXRA—thyroid cancer	1.31e-06	1.19e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—thyroid cancer	1.3e-06	1.19e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PPARG—thyroid cancer	1.29e-06	1.18e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PTEN—thyroid cancer	1.29e-06	1.18e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—thyroid cancer	1.29e-06	1.18e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—NRAS—thyroid cancer	1.28e-06	1.16e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.27e-06	1.16e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—thyroid cancer	1.27e-06	1.16e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—thyroid cancer	1.27e-06	1.16e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—thyroid cancer	1.26e-06	1.15e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—thyroid cancer	1.26e-06	1.15e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—thyroid cancer	1.26e-06	1.15e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NRAS—thyroid cancer	1.26e-06	1.15e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—thyroid cancer	1.26e-06	1.15e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—thyroid cancer	1.24e-06	1.13e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NRAS—thyroid cancer	1.23e-06	1.12e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—thyroid cancer	1.23e-06	1.12e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—thyroid cancer	1.22e-06	1.12e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—thyroid cancer	1.21e-06	1.11e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NRAS—thyroid cancer	1.21e-06	1.11e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—thyroid cancer	1.21e-06	1.11e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—thyroid cancer	1.21e-06	1.1e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—thyroid cancer	1.2e-06	1.1e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—thyroid cancer	1.2e-06	1.1e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.2e-06	1.09e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—thyroid cancer	1.19e-06	1.09e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—thyroid cancer	1.17e-06	1.07e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NRAS—thyroid cancer	1.17e-06	1.07e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—thyroid cancer	1.17e-06	1.06e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—thyroid cancer	1.16e-06	1.06e-05	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—thyroid cancer	1.16e-06	1.06e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NRAS—thyroid cancer	1.15e-06	1.05e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—thyroid cancer	1.15e-06	1.05e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—thyroid cancer	1.14e-06	1.04e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTEN—thyroid cancer	1.13e-06	1.03e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—thyroid cancer	1.13e-06	1.03e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—thyroid cancer	1.12e-06	1.02e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—thyroid cancer	1.1e-06	1e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—thyroid cancer	1.08e-06	9.88e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—thyroid cancer	1.08e-06	9.85e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—thyroid cancer	1.08e-06	9.83e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—thyroid cancer	1.07e-06	9.74e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—thyroid cancer	1.07e-06	9.73e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—thyroid cancer	1.06e-06	9.7e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—thyroid cancer	1.06e-06	9.67e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—thyroid cancer	1.05e-06	9.62e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—thyroid cancer	1.04e-06	9.52e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—thyroid cancer	1.04e-06	9.47e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARG—thyroid cancer	1.03e-06	9.43e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—thyroid cancer	1.02e-06	9.32e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—thyroid cancer	1.02e-06	9.28e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—thyroid cancer	1.01e-06	9.23e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NRAS—thyroid cancer	1.01e-06	9.21e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—thyroid cancer	1.01e-06	9.2e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—RXRA—thyroid cancer	1.01e-06	9.2e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—thyroid cancer	1e-06	9.17e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTEN—thyroid cancer	1e-06	9.14e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—thyroid cancer	9.91e-07	9.05e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—thyroid cancer	9.62e-07	8.78e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—thyroid cancer	9.52e-07	8.69e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—thyroid cancer	9.41e-07	8.6e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTEN—thyroid cancer	9.39e-07	8.57e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—thyroid cancer	9.33e-07	8.52e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—thyroid cancer	9.3e-07	8.5e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—thyroid cancer	9.27e-07	8.46e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—thyroid cancer	9.2e-07	8.4e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—thyroid cancer	9.01e-07	8.23e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—thyroid cancer	9e-07	8.22e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NRAS—thyroid cancer	8.93e-07	8.15e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—thyroid cancer	8.92e-07	8.15e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—thyroid cancer	8.92e-07	8.15e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTEN—thyroid cancer	8.87e-07	8.1e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—thyroid cancer	8.86e-07	8.09e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—thyroid cancer	8.81e-07	8.04e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—thyroid cancer	8.68e-07	7.93e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—thyroid cancer	8.53e-07	7.79e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—thyroid cancer	8.43e-07	7.69e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—thyroid cancer	8.3e-07	7.58e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARG—thyroid cancer	8.24e-07	7.52e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—thyroid cancer	8.24e-07	7.52e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—thyroid cancer	8.12e-07	7.41e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—thyroid cancer	8.12e-07	7.41e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—thyroid cancer	7.95e-07	7.26e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—thyroid cancer	7.83e-07	7.15e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—thyroid cancer	7.72e-07	7.05e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—thyroid cancer	7.69e-07	7.02e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—thyroid cancer	7.55e-07	6.89e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—thyroid cancer	7.54e-07	6.88e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—thyroid cancer	7.44e-07	6.79e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—thyroid cancer	7.38e-07	6.74e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTEN—thyroid cancer	7.08e-07	6.47e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—thyroid cancer	6.83e-07	6.24e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—thyroid cancer	6.53e-07	5.96e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—thyroid cancer	6.52e-07	5.95e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—thyroid cancer	6.48e-07	5.92e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARG—thyroid cancer	6.36e-07	5.81e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—thyroid cancer	5.77e-07	5.27e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTEN—thyroid cancer	5.65e-07	5.16e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—thyroid cancer	5.41e-07	4.94e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—thyroid cancer	5.11e-07	4.67e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—thyroid cancer	5e-07	4.57e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTEN—thyroid cancer	4.36e-07	3.98e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—thyroid cancer	4.08e-07	3.73e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—thyroid cancer	3.26e-07	2.97e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—thyroid cancer	2.51e-07	2.3e-06	CbGpPWpGaD
